PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24374180-0 2014 A specific inhibitor of CDK1, RO-3306, reversibly arrests meiosis during in vitro maturation of porcine oocytes. RO 3306 30-37 cyclin dependent kinase 1 Homo sapiens 24-28 24378347-0 2014 The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition. RO 3306 19-25 cyclin dependent kinase 1 Homo sapiens 4-8 24321771-8 2014 RO-3306, a cdk-1 inhibitor, induced a 90% arrest in G2/M reversible in less than 15min. RO 3306 0-7 cyclin dependent kinase 1 Homo sapiens 11-16 24374180-2 2014 In this study, we investigated the possibility of utilizing a selective inhibitor of CDK1, RO-3306, as a novel agent for the synchronization of oocyte maturation. RO 3306 91-98 cyclin dependent kinase 1 Homo sapiens 85-89 24374180-10 2014 RO-3306 treatment increased expression of CDK1 but had no effect on the expression of the other genes. RO 3306 0-7 cyclin dependent kinase 1 Homo sapiens 42-46 24626186-2 2014 In this study we utilized low doses of the Cdk1-specific inhibitor, RO3306 from early G 2 phase onwards. RO 3306 68-74 cyclin dependent kinase 1 Homo sapiens 43-47 24626186-7 2014 Furthermore, cells treated with medium doses of RO3306 were only able to reach the threshold of Cdk1 substrate phosphorylation required to initiate nuclear envelope breakdown, but failed to reach the levels of phosphorylation required to correctly complete pro-metaphase. RO 3306 48-54 cyclin dependent kinase 1 Homo sapiens 96-100 24195507-0 2014 Cyclin-dependent kinase 1 inhibitor RO3306 promotes mitotic slippage in paclitaxel-treated HepG2 cells. RO 3306 36-42 cyclin dependent kinase 1 Homo sapiens 0-25 24195507-4 2014 We investigated the effect of a sequential combination of PTX and RO3306, a cyclin-dependent kinase 1 inhibitor, on the hepatocellular carcinoma HepG2 cell line. RO 3306 66-72 cyclin dependent kinase 1 Homo sapiens 76-101 20661218-6 2010 Whereas RO-3306, a selective inhibitor of cyclin-dependent kinase 1 (Cdk1), suppresses this phosphorylation at Ser315 of p53, ZM447439, targeting Aurora A/B kinases, shows no effect. RO 3306 8-15 cyclin dependent kinase 1 Homo sapiens 42-67 24091728-4 2013 Using synchronized HeLa cells released from a double thymidine block (G 1/S boundary) or the Cdk1 inhibitor, RO3306 (G 2/M boundary), we have systematically re-addressed this dogma. RO 3306 109-115 cyclin dependent kinase 1 Homo sapiens 93-97 23525902-5 2013 We rescued cells lethally depleted of endogenous Cdk1 with an exogenous Cdk1 conferring sensitivity to one ATP analogue inhibitor (1NMPP1) and resistance to another (RO3306). RO 3306 166-172 cyclin dependent kinase 1 Homo sapiens 49-53 23525902-5 2013 We rescued cells lethally depleted of endogenous Cdk1 with an exogenous Cdk1 conferring sensitivity to one ATP analogue inhibitor (1NMPP1) and resistance to another (RO3306). RO 3306 166-172 cyclin dependent kinase 1 Homo sapiens 72-76 23525902-7 2013 We also rescued RO3306-resistant clones using exogenous Cdk1 without inhibitory phosphorylation sites, indicating that the mitotic surge of Cdk1 activity is dispensable for cell proliferation. RO 3306 16-22 cyclin dependent kinase 1 Homo sapiens 56-60 23525902-7 2013 We also rescued RO3306-resistant clones using exogenous Cdk1 without inhibitory phosphorylation sites, indicating that the mitotic surge of Cdk1 activity is dispensable for cell proliferation. RO 3306 16-22 cyclin dependent kinase 1 Homo sapiens 140-144 20937773-5 2010 Furthermore, RNA interference-mediated silencing of cyclin B1 or treatment with the Cdk1 inhibitor RO-3306 enhances the Fas-mediated activation and processing of procaspase-8 in mitotic cells. RO 3306 99-106 cyclin dependent kinase 1 Homo sapiens 84-88 22071694-7 2011 The Cdk1 inhibitors, RO-3306 and Purvalanol A, block Bim phosphorylation in mitotically arrested cells. RO 3306 21-28 cyclin dependent kinase 1 Homo sapiens 4-8 20661218-6 2010 Whereas RO-3306, a selective inhibitor of cyclin-dependent kinase 1 (Cdk1), suppresses this phosphorylation at Ser315 of p53, ZM447439, targeting Aurora A/B kinases, shows no effect. RO 3306 8-15 cyclin dependent kinase 1 Homo sapiens 69-73 19822658-2 2009 Inhibition of cyclin-dependent kinase 1 (CDK1) with the specific inhibitor RO3306 is sufficient to trigger multiple rounds of genome reduplication. RO 3306 75-81 cyclin dependent kinase 1 Homo sapiens 14-39 20736311-5 2010 Studies aimed at identifying these kinases suggested that CDK1 activity is required to sustain Erk5 phosphorylation in mitosis, as treatment with RO3306, a CDK1 inhibitor, reversed mitotic phosphorylation of Erk5. RO 3306 146-152 cyclin dependent kinase 1 Homo sapiens 58-62 20736311-5 2010 Studies aimed at identifying these kinases suggested that CDK1 activity is required to sustain Erk5 phosphorylation in mitosis, as treatment with RO3306, a CDK1 inhibitor, reversed mitotic phosphorylation of Erk5. RO 3306 146-152 cyclin dependent kinase 1 Homo sapiens 156-160 20172609-2 2010 48-h serum deprival, and a 24-h treatment with 1 mM hydroxyurea or with 10 microM RO-3306--a cyclin-dependent kinase 1 inhibitor--induced cell cycle block in G1, S and G2/M, respectively. RO 3306 82-89 cyclin dependent kinase 1 Homo sapiens 93-118 19822658-2 2009 Inhibition of cyclin-dependent kinase 1 (CDK1) with the specific inhibitor RO3306 is sufficient to trigger multiple rounds of genome reduplication. RO 3306 75-81 cyclin dependent kinase 1 Homo sapiens 41-45 18981479-3 2008 Here we show that RO3306 inhibition of cyclin-dependent protein kinase 1 (CDK1), the enzyme required to enter mitosis, induced differentiation of TS cells into TG cells. RO 3306 18-24 cyclin dependent kinase 1 Homo sapiens 39-72 18981479-3 2008 Here we show that RO3306 inhibition of cyclin-dependent protein kinase 1 (CDK1), the enzyme required to enter mitosis, induced differentiation of TS cells into TG cells. RO 3306 18-24 cyclin dependent kinase 1 Homo sapiens 74-78 18981479-4 2008 In contrast, RO3306 induced abortive endoreduplication and apoptosis in embryonic stem cells, revealing that inactivation of CDK1 triggers endoreduplication only in cells programmed to differentiate into polyploid cells. RO 3306 13-19 cyclin dependent kinase 1 Homo sapiens 125-129 34435645-8 2021 Therefore, dysfunction of CDK1/cyclin B1 could be defining the loss of paclitaxel lethality against cancer cells, a phenomenon affirmed by the CDK1 inhibitor Ro3306. RO 3306 158-164 cyclin dependent kinase 1 Homo sapiens 26-30 17172841-4 2006 Recently, a selective CDK1 inhibitor, RO-3306, has been identified that reversibly arrests proliferating human cells at the G2/M phase border and provides a novel means for cell cycle synchronization. RO 3306 38-45 cyclin dependent kinase 1 Homo sapiens 22-26 17172841-7 2006 RO-3306 represents a new molecular tool for studying CDK1 function in human cells. RO 3306 0-7 cyclin dependent kinase 1 Homo sapiens 53-57 34435645-8 2021 Therefore, dysfunction of CDK1/cyclin B1 could be defining the loss of paclitaxel lethality against cancer cells, a phenomenon affirmed by the CDK1 inhibitor Ro3306. RO 3306 158-164 cyclin dependent kinase 1 Homo sapiens 143-147 34611473-3 2021 To further investigate the molecular mechanism of HIF-1alpha destabilization by CDK1 or CDK4/6 inhibitors, we performed a proteomic screen on immunoprecipitated HIF-1alpha from hypoxic colorectal cancer cells that were either untreated or treated with CDK1 inhibitor Ro3306 and CDK4/6 inhibitor palbociclib. RO 3306 267-273 cyclin dependent kinase 1 Homo sapiens 252-256 34267439-7 2021 There was a non-significant inverse correlation between vitamin D and CDK-1 (before RO-3306 addition) and a positive correlation after RO-3306. RO 3306 84-91 cyclin dependent kinase 1 Homo sapiens 70-75 34267439-9 2021 However, a significant positive correlation was found between CDK-1 (after RO-3306 addition) and proteinuria. RO 3306 75-82 cyclin dependent kinase 1 Homo sapiens 62-67 34267439-11 2021 There was a positive correlation between CDK-1 gene expression and CRP before and after RO-3306 addition. RO 3306 88-95 cyclin dependent kinase 1 Homo sapiens 41-46 35367281-0 2022 The CDK1 inhibitor, Ro-3306, is a potential antiviral candidate against influenza virus infection. RO 3306 20-27 cyclin dependent kinase 1 Homo sapiens 4-8 35367281-4 2022 We conducted this study to investigate the potential of the CDK1 inhibitor Ro-3306 in preventing influenza virus infection and to elucidate the underlying mechanism. RO 3306 75-82 cyclin dependent kinase 1 Homo sapiens 60-64 35367281-5 2022 We showed that Ro-3306, a CDK1 inhibitor, exerts anti-influenza activity both in vitro and in vivo. RO 3306 15-22 cyclin dependent kinase 1 Homo sapiens 26-30 35443178-5 2022 Unexpectedly, we find that the commonly used CDK1 inhibitor RO3306 interferes with replication to preclude detection of G2 DNA synthesis, leading to the impression of a mitosis-driven response. RO 3306 60-66 cyclin dependent kinase 1 Homo sapiens 45-49 33684621-5 2021 We performed immunofluorescence and flow cytometry analysis to investigate DNA damage responses in human tumor cells during low and high dose treatments with RO-3306, a selective CDK1 inhibitor. RO 3306 158-165 cyclin dependent kinase 1 Homo sapiens 179-183 33727226-10 2021 Importantly, a pharmacological inhibitor of CDK1, RO-3306, disrupted GIST cell proliferation in CDK1 highly expressed GIST but not in CDK1-negative GIST cells and non-transformed fibroblast cells. RO 3306 50-57 cyclin dependent kinase 1 Homo sapiens 44-48 33727226-10 2021 Importantly, a pharmacological inhibitor of CDK1, RO-3306, disrupted GIST cell proliferation in CDK1 highly expressed GIST but not in CDK1-negative GIST cells and non-transformed fibroblast cells. RO 3306 50-57 cyclin dependent kinase 1 Homo sapiens 96-100 33727226-10 2021 Importantly, a pharmacological inhibitor of CDK1, RO-3306, disrupted GIST cell proliferation in CDK1 highly expressed GIST but not in CDK1-negative GIST cells and non-transformed fibroblast cells. RO 3306 50-57 cyclin dependent kinase 1 Homo sapiens 96-100 32948832-8 2021 Moreover, the combination of CDK1 inhibition (mediated by RO3306) and miR-34c-3p overexpression resulted in an additive effect on the viability of KRASmut-expressing cells. RO 3306 58-64 cyclin dependent kinase 1 Homo sapiens 29-33 29435156-5 2018 Cis-3M-RES-induced phosphorylation of BCL-2 family proteins and mitochondrial apoptotic events were suppressed by a validated CDK1 inhibitor RO3306. RO 3306 141-147 cyclin dependent kinase 1 Homo sapiens 126-130 33707466-8 2021 Targeted knockdown of CDK1 or chemical inhibition with the selective CDK1 inhibitor, RO-3306, potentiated the cytotoxic effect of TMZ. RO 3306 85-92 cyclin dependent kinase 1 Homo sapiens 22-26 33707466-8 2021 Targeted knockdown of CDK1 or chemical inhibition with the selective CDK1 inhibitor, RO-3306, potentiated the cytotoxic effect of TMZ. RO 3306 85-92 cyclin dependent kinase 1 Homo sapiens 69-73 29760710-5 2018 The latter was sensitive to inhibition by the immunosuppressant cyclosporine A, Ca2+ buffer BAPTA-AM, and the CDK1-inhibitor RO3306, indicating the involvement of Ca2+-dependent immune activation and radiation-induced cell cycle arrest. RO 3306 125-131 cyclin dependent kinase 1 Homo sapiens 110-114 29233910-4 2018 BRAFV600E colorectal cancer cell lines expressing CDK1 were sensitized to apoptosis upon siRNA knockdown or small-molecule inhibition with RO-3306 (CDK1 inhibitor) or dinaciclib (CDK1, 2, 5, 9 inhibitors). RO 3306 139-146 cyclin dependent kinase 1 Homo sapiens 50-54 29233910-4 2018 BRAFV600E colorectal cancer cell lines expressing CDK1 were sensitized to apoptosis upon siRNA knockdown or small-molecule inhibition with RO-3306 (CDK1 inhibitor) or dinaciclib (CDK1, 2, 5, 9 inhibitors). RO 3306 139-146 cyclin dependent kinase 1 Homo sapiens 148-152 29233910-4 2018 BRAFV600E colorectal cancer cell lines expressing CDK1 were sensitized to apoptosis upon siRNA knockdown or small-molecule inhibition with RO-3306 (CDK1 inhibitor) or dinaciclib (CDK1, 2, 5, 9 inhibitors). RO 3306 139-146 cyclin dependent kinase 1 Homo sapiens 148-152 30045664-3 2018 Radiosensitization by the specific CDK1 inhibitor, RO-3306, was determined by colony formation assays in three tumor lines (HeLa, T24, SQ20B) and three non-cancer lines (HFL1, MRC-5, RPE). RO 3306 51-58 cyclin dependent kinase 1 Homo sapiens 35-39 33556637-6 2021 Subsequently, we found that after rescuing TPX2, all related proteins and phenotype changes were restored, and this effect can be inhibited by CDK1 inhibitor, RO-3306. RO 3306 159-166 cyclin dependent kinase 1 Homo sapiens 143-147 30273737-4 2019 In the first experiment, matured oocytes were exposed to ionomycin (Ion) for 5 min, and then treated with a specific CDK1 inhibitor (RO-3306) and/or PKC activator (OAG) for different time intervals. RO 3306 133-140 cyclin dependent kinase 1 Homo sapiens 117-121 30083256-0 2018 Blocking CDK1/PDK1/beta-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. RO 3306 60-66 cyclin dependent kinase 1 Homo sapiens 9-13 30083256-0 2018 Blocking CDK1/PDK1/beta-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. RO 3306 60-66 cyclin dependent kinase 1 Homo sapiens 45-49 30083256-7 2018 CDK1 inhibitor RO3306 in combination with sorafenib treatment significantly decreased tumor growth in PDX tumor models. RO 3306 15-21 cyclin dependent kinase 1 Homo sapiens 0-4 30083256-12 2018 Mechanistic and functional studies silencing CDK1 with shRNA and RO3306 combined with sorafenib abolished oncogenic function via downregulating CDK1, with downstream PDK1 and beta-Catenin inactivation. RO 3306 65-71 cyclin dependent kinase 1 Homo sapiens 45-49 30083256-12 2018 Mechanistic and functional studies silencing CDK1 with shRNA and RO3306 combined with sorafenib abolished oncogenic function via downregulating CDK1, with downstream PDK1 and beta-Catenin inactivation. RO 3306 65-71 cyclin dependent kinase 1 Homo sapiens 144-148 29884303-8 2018 Effect of Cyclin Dependent Kinase 1 (CDK1) inhibitor, RO3306, on BeWo cell fusion was studied by microscopy and FACS, and by monitoring the expression of human Chorionic Gonadotropin (hCG) by Western blotting and qPCR. RO 3306 54-60 cyclin dependent kinase 1 Homo sapiens 10-35 29884303-8 2018 Effect of Cyclin Dependent Kinase 1 (CDK1) inhibitor, RO3306, on BeWo cell fusion was studied by microscopy and FACS, and by monitoring the expression of human Chorionic Gonadotropin (hCG) by Western blotting and qPCR. RO 3306 54-60 cyclin dependent kinase 1 Homo sapiens 37-41 27120680-4 2016 Moreover, the inhibition effect of inhibitors on multiple kinases could be simultaneously readout in a single electrophoretic run, with half maximal inhibitory concentration of H-89 for PKA and Ro-3306 for CDK1 calculated as 37.0 and 35.9 nM, respectively, consistent with literatures reported. RO 3306 194-201 cyclin dependent kinase 1 Homo sapiens 206-210 28678347-6 2017 Consistently, the CDK1 inhibitor RO-3306 is less active in a TRAP1-high background. RO 3306 33-40 cyclin dependent kinase 1 Homo sapiens 18-22 28434945-8 2017 In cellular models, inhibition of CDK1 by siRNA or a specific inhibitor, RO-3306, reduced cellular proliferation and viability for HCC cells. RO 3306 73-80 cyclin dependent kinase 1 Homo sapiens 34-38 27212103-0 2016 Jumping the nuclear envelop barrier: Improving polyplex-mediated gene transfection efficiency by a selective CDK1 inhibitor RO-3306. RO 3306 124-131 cyclin dependent kinase 1 Homo sapiens 109-113 27212103-4 2016 To jump the nuclear envelope barrier, we used a selective and reversible CDK1 inhibitor RO-3306 to control the G2/M transition of the cell cycle and increased the proportion of mitotic cells which have disappeared nuclear envelope during transfection. RO 3306 88-95 cyclin dependent kinase 1 Homo sapiens 73-77 27385216-6 2016 When the expression and activity of Cdk1 were inhibited by si-Cdk1 or RO-3306 which is a potent Cdk1 inhibitor, the growth of ovarian cancer was diminished. RO 3306 70-77 cyclin dependent kinase 1 Homo sapiens 36-40 27134283-4 2016 To increase our understanding of Cdk1-dependent phosphorylation pathways in mitosis, we conducted a quantitative phosphoproteomics analysis in mitotic HeLa cells using two small molecule inhibitors of Cdk1, Flavopiridol and RO-3306. RO 3306 224-231 cyclin dependent kinase 1 Homo sapiens 33-37 26046302-6 2016 Mechanistically, BI 2536/VCR co-treatment triggers prolonged mitotic arrest, which is necessary for BI 2536/VCR-mediated apoptosis, since pharmacological inhibition of mitotic arrest by the CDK1 inhibitor RO-3306 significantly reduces cell death. RO 3306 205-212 cyclin dependent kinase 1 Homo sapiens 190-194 27050151-8 2016 The ORL lines noted to be enriched in cell cycle genes responded preferentially to the CDK1 inhibitor RO3306, by MTT cell viability assay. RO 3306 102-108 cyclin dependent kinase 1 Homo sapiens 87-91 25388513-8 2015 Finally, we tested CDK1 inhibitor RO-3306, which impairs HR by inhibiting CDK1-mediated BRCA1 phosphorylation. RO 3306 34-41 cyclin dependent kinase 1 Homo sapiens 19-23 25917079-7 2015 On molecular grounds, Eribulin/BI 2536 co-treatment causes profound mitotic arrest, which is critically required for synergism, since inhibition of mitotic arrest by CDK1 inhibitor RO-3306 abolishes Eribulin/BI 2536-mediated apoptosis. RO 3306 181-188 cyclin dependent kinase 1 Homo sapiens 166-170 25388513-8 2015 Finally, we tested CDK1 inhibitor RO-3306, which impairs HR by inhibiting CDK1-mediated BRCA1 phosphorylation. RO 3306 34-41 cyclin dependent kinase 1 Homo sapiens 74-78